﻿<?xml version="1.0" encoding="utf-8"?><rss version="2.0"><channel><title>Silicon Investor - Essential Therapeutics (ETRX) formerly Microcide (MCDE</title><copyright>Copyright © 2026 Knight Sac Media.  All rights reserved.</copyright><link>https://www.siliconinvestor.com/subject.aspx?subjectid=19072</link><description>
Microcide is postioned well in a key biotech area--finding solutions to antibiotic resistant bacteria.  This area has been overlooked in the last decade, with most  the emphasis on viral/AIDS research.  Now we have strains of bacteria which are resistant to all antibiotics, including the "silver bullet" Vancomycin.   MCDE has the management and techical ability to accomplish the task--it's better positioned than any other company as a pure play in this area of biotech.</description><image><url>https://www.siliconinvestor.com/images/Logo380x132.png</url><title>SI - Essential Therapeutics (ETRX) formerly Microcide (MCDE</title><link>https://www.siliconinvestor.com/subject.aspx?subjectid=19072</link><width>380</width><height>132</height></image><ttl>10</ttl></channel></rss>